Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis.

J Transl Med · 2014 · PMC4237886 · PMID 25082261

Europe PMC DOI

hedged sentence

0.0320

closest p · 0.6× alpha

0.0320

boldest claim

The sentences

a significant trendp = 0.032actually significant

High expression of Aurora-A associated with a significant trend toward worse OS and PFS in patients of stage I ( p = 0.032 for OS and p = 0.007 for PFS, Figure 3 A and B), stage II ( p = 0.026 for OS and p = 0.038 for PFS, Figure 3 C and D), and stage III ( p = 0.017 for OS and p = 0.002 for PFS, Figure 3 E and F).

also in 6,248 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.